Related Articles by Review for PMID: 35881757

Year	Number of Results
2020	1
2021	3
2022	9
2023	20
2024	6
2025	1

1

Bello J, Pellegrini MV. Bello J, et al. 2024 Aug 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Aug 21. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 35881757 Free Books & Documents.

2

New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.

Woodland M, Al-Horani RA. Woodland M, et al. Cardiovasc Hematol Agents Med Chem. 2023;21(2):78-83. doi: 10.2174/1871525721666221019095218. Cardiovasc Hematol Agents Med Chem. 2023. PMID: 36278454 Free PMC article. Review.

3

Mavacamten: First Approval.

Keam SJ. Keam SJ. Drugs. 2022 Jul;82(10):1127-1135. doi: 10.1007/s40265-022-01739-7. Epub 2022 Jul 8. Drugs. 2022. PMID: 35802255 Free PMC article. Review.

4

Mavacamten: A Novel Agent for Hypertrophic Cardiomyopathy.

Chase Cole J, Benvie SF, DeLosSantos M. Chase Cole J, et al. Clin Ther. 2024 Apr;46(4):368-373. doi: 10.1016/j.clinthera.2024.02.007. Epub 2024 Mar 19. Clin Ther. 2024. PMID: 38508915 Review.

5

An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults.

Dong T, Nissen S, Ospina S, Desai MY. Dong T, et al. Expert Rev Cardiovasc Ther. 2023 Jan;21(1):5-13. doi: 10.1080/14779072.2023.2159811. Epub 2022 Dec 22. Expert Rev Cardiovasc Ther. 2023. PMID: 36522857 Review.

6

Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy.

Zampieri M, Argirò A, Marchi A, Berteotti M, Targetti M, Fornaro A, Tomberli A, Stefàno P, Marchionni N, Olivotto I. Zampieri M, et al. Curr Cardiol Rep. 2021 Jun 3;23(7):79. doi: 10.1007/s11886-021-01508-0. Curr Cardiol Rep. 2021. PMID: 34081217 Review.

7

Efficacy and Safety of Mavacamten in the Treatment of Hypertrophic Cardiomyopathy: A Systematic Review.

Bishev D, Fabara S, Loseke I, Alok A, Al-Ani H, Bazikian Y. Bishev D, et al. Heart Lung Circ. 2023 Sep;32(9):1049-1056. doi: 10.1016/j.hlc.2023.05.019. Epub 2023 Jul 14. Heart Lung Circ. 2023. PMID: 37453852 Free article. Review.

8

Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy.

Tower-Rader A, Ramchand J, Nissen SE, Desai MY. Tower-Rader A, et al. Expert Opin Investig Drugs. 2020 Nov;29(11):1171-1178. doi: 10.1080/13543784.2020.1821361. Epub 2020 Sep 20. Expert Opin Investig Drugs. 2020. PMID: 32897741 Review.

9

Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy.

Braunwald E, Saberi S, Abraham TP, Elliott PM, Olivotto I. Braunwald E, et al. Eur Heart J. 2023 Nov 21;44(44):4622-4633. doi: 10.1093/eurheartj/ehad637. Eur Heart J. 2023. PMID: 37804245 Free PMC article. Review.

10

Mavacamten: A First-in-class Oral Modulator of Cardiac Myosin for the Treatment of Symptomatic Hypertrophic Obstructive Cardiomyopathy.

Reyes KRL, Bilgili G, Rader F. Reyes KRL, et al. Heart Int. 2022 Oct 5;16(2):91-98. doi: 10.17925/HI.2022.16.2.91. eCollection 2022. Heart Int. 2022. PMID: 36741099 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

35 results

Results by year

Filters

My Custom Filters

Results by year

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Related Articles by Review for PMID: 35881757

35 results

Results by year